Celladon is dedicated to the treatment of cardiac diseases through the use of new technologies in molecular cardiology.  Celladon’s products are first-in-class drugs that target the key enzyme deficiency in severe heart failure, SERCA2a. A key underpinning of heart failure is the depletion of SERCA2a enzyme in heart muscle cells, which results in abnormal intracellular calcium cycling and poor contractility. Our research shows that recombinant adeno-associated viral vectors (AAV) are ideal for restoring SERCA2a enzyme production via cardiac muscle gene transfer.

Click on the links below for Celladon's Product Overview.